MDH2-IN-2
MDH2-IN-2 is an orally active MDH2 inhibitor with an IC50 of 5.9 μM. MDH2-IN-2 reduces the levels of senescence markers and senescence-associated secretory phenotype (SASP) factors in mammalian cell models. MDH2-IN-2 extends the lifespan and improves the healthspan of Caenorhabditis elegans. MDH2-IN-2 alleviates tissue senescence in aged mice, inhibits SASP factors, and restores liver and kidney functions. MDH2-IN-2 is applicable for senescence-related research.
For research use only. We do not sell to patients.
- CAS No.: 3047410-41-0
- Formula: C31H40N2O4S
- Molecular Weight:536.73
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
MDH2-IN-2 (Compound 28i) inhibits the activity of recombinant human MDH1 enzyme, with an IC50 value of 25.3 μM[1].
MDH2-IN-2 (1 μM; 3 days) significantly downregulates the mRNA levels of various SASP factors in MRC-5 cells, and reduces the expression level of p53 protein and the proportion of SA-β-gal-positive cells in replicatively senescent MRC-5 cells[1].
MDH2-IN-2 (1 μM) significantly reduces the proportion of SA-β-gal-positive NRK-52E cells that undergo senescence induced by Mitomycin C (HY-13316)[1].
MDH2-IN-2 (1 μM; 5 days) significantly reduces the expression level of p16 protein and the proportion of SA-β-gal positive cells in replicative senescent MEFs[1].
MDH2-IN-2 (1 μM; 5-60 minutes) undergoes rapid metabolic turnover in both human and mouse liver microsomes, with corresponding T1/2 values of 1.15 min and 1.10 min, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MRC-5 cells
-
Concentration:1 μM
-
Incubation Time:3 days
-
Result:Significantly downregulated mRNA expression of senescence-associated secretory phenotype (SASP) factors IL-1α, IL-1β, IL-8, CXCL-1, MMP-1, and MMP-3.
-
Cell Line:Replicatively senescent human embryonic lung fibroblasts (MRC-5, passage 32)
-
Concentration:1 μM
-
Incubation Time:3 days
-
Result:Significantly reduced the protein expression level of p53, a key senescence-associated cell cycle regulator.
-
Cell Line:Replicatively senescent mouse embryonic fibroblasts (MEFs, passage 7)
-
Concentration:1 μM
-
Incubation Time:5 days
-
Result:Significantly reduced the protein expression level of p16, a key senescence-associated cyclin-dependent kinase inhibitor.
MDH2-IN-2 (0-50 mg/kg; i.g.; once daily; 3 weeks) significantly inhibits multiple SASP factors in premature senescent male C57BL/6J mice induced by Doxorubicin (HY-15142A)[1].
MDH2-IN-2 (5-10 mg/kg; i.g.; once daily; 3 months) reverses age-related serum biochemical abnormalities, inhibits the production of SASP factors, reduces the expression of renal senescence markers, and improves renal histological morphology in naturally aged male C57BL/6J mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:wild-type N2[1]
-
Dosage:100 μM
-
Administration:incorporation into NGM plates; continuous exposure
-
Result:Extended mean lifespan by 15.49% compared to controls.
Significantly improved egg-laying capacity compared to controls.
Increased pharyngeal pumping rate compared to controls.
Maintained body bend frequency relative to controls.
-
Animal Model:C57BL/6J (male, 8 weeks old, doxorubicin-induced premature aging)[1]
-
Dosage:10 mg/kg; 20 mg/kg; 50 mg/kg
-
Administration:i.g.; once daily; 3 weeks
-
Result:Significantly reduced serum levels of SASP factors including IL-1β, IL-6, CXCL-1, TNF-α, MMP-1, and MMP-2 compared to Dox-only treated male mice.
-
Animal Model:C57BL/6J (male, 21 months old, naturally aged)[1]
-
Dosage:5 mg/kg; 10 mg/kg
-
Administration:i.g.; once daily; 3 months
-
Result:Significantly reduced age-related increases in serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and uric acid (UA) to levels comparable to young control mice.
Markedly reduced serum levels of SASP factors including IL-6, IL-1β, MMP-1, MMP-2, CXCL-1, GDF-15, and TNF-α.
Downregulated renal tissue expression of senescence markers p53, p21, and p16.
Significantly ameliorated age-related glomerular atrophy, inflammatory infiltration, and collagen fiber accumulation in the kidney.
Chemical Information
-
CAS No. 3047410-41-0
-
Molecular Weight 536.73
-
Formula C31H40N2O4S
-
SMILES
O=S(C1=CC=C(C=C1)CCNC(C2=CC=CC(OCC3CCCC3)=C2)=O)(NC45C[C@@H]6C[C@H](C5)C[C@@H](C6)C4)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)